PATENT CLAIM ANALYSIS

Application Number: 15765040
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "280000"]

Abstract:
Trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues as DNMT inhibitors for use as a drug for the treatment of cancer and neurological diseases and for cell reprogramming, in particular to prime for chemotherapy or immunotherapy.

Claim (Index 31):
The method according to  claim 30 , wherein trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues are selected from the group consisting of trilobine, isotrilobine, O-methylcocsoline, cocsuline, 2\u2032-norcocsuline, cocsoline, nortrilobine, 1,2-dehydroapateline, 1,2-dehydrotelobine and the pharmaceutically acceptable salts and solvates thereof.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 90.0
- Lexical Diversity: 1.1875
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15765048', '12528020', '15775746', '15508063', '15315326']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7572295704392686
- 35 USC 102 Novelty (BERT): 0.5184449717121644
- Combined Prediction Score: 0.7333511105665582
- Mean Citation Score: 217.78997400000003
- Max Citation Score: 284.20834
- Similarity Product: 198.40198844897628

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test